Qube Research & Technologies LTD Krystal Biotech, Inc. Transaction History

Qube Research & Technologies LTD

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$108.01 - $179.35 $46,552 - $77,299	-431 Reduced 8.7%	4,523 $804,000
Q4 2023 Feb 13, 2024	SELL	$96.0 - $128.29 $782,976 - $1.05 Million	-8,156 Reduced 62.21%	4,954 $614,000
Q3 2023 Nov 13, 2023	BUY	$108.51 - $130.22 $358,625 - $430,377	3,305 Added 33.71%	13,110 $1.52 Million
Q2 2023 Aug 14, 2023	BUY	$78.48 - $130.32 $769,496 - $1.28 Million	9,805 New	9,805 $1.15 Million
Q4 2022 Feb 14, 2023	BUY	$63.14 - $79.9 $1.21 Million - $1.54 Million	19,224 New	19,224 $1.52 Million
Q4 2021 Feb 01, 2022	SELL	$39.81 - $88.24 $290,294 - $643,446	-7,292 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$52.01 - $71.77 $67,977 - $93,803	1,307 Added 21.84%	7,292 $381,000
Q2 2021 Aug 13, 2021	BUY	$62.14 - $81.82 $371,907 - $489,692	5,985 New	5,985 $407,000
Q3 2020 Nov 12, 2020	SELL	$37.76 - $48.49 $187,440 - $240,704	-4,964 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$37.03 - $60.0 $183,816 - $297,840	4,964 New	4,964 $206,000
Q1 2020 May 15, 2020	SELL	$35.02 - $65.64 $313,849 - $588,265	-8,962 Closed	0 $0
Q4 2019 Feb 13, 2020	BUY	$33.17 - $65.23 $297,269 - $584,591	8,962 New	8,962 $496,000

310

24.4M

483K

364K

Ticker KRYS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,664,300
Market Cap $4.89B
Description
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

Stay updated on Qube Research & Technologies LTD with notifications on news.